• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊朗伊斯法罕的多发性硬化症

Multiple sclerosis in Isfahan, Iran.

作者信息

Saadatnia Mohammad, Etemadifar Masoud, Maghzi Amir Hadi

机构信息

Department of Neurology, Isfahan University of Medical Sciences, Isfahan 81744, Iran.

出版信息

Int Rev Neurobiol. 2007;79:357-75. doi: 10.1016/S0074-7742(07)79016-5.

DOI:10.1016/S0074-7742(07)79016-5
PMID:17531850
Abstract

BACKGROUND

This survey was planned to study the prevalence and incidence of multiple sclerosis (MS) in Isfahan, Iran and to describe the clinical features of MS in general and in specific subgroups of patients (early-onset, late-onset, familial, and conjugal cases) and to compare our results with other reports.

METHODS

A cross-sectional study was conducted from April 5, 2003 to July 31, 2006. All patients known to have definite MS according to McDonald's criteria, alive, resident within Isfahan (a large province of Iran) and members of Isfahan MS Society (IMSS) were included in the study. Demographic and case-related information were recorded. A total number of 1718 definite MS patients (388 men and 1330 women) were identified from IMSS database.

RESULTS

The overall period prevalence of MS was 43.8/100,000. Among men the prevalence was 19.2 (95% CI: 17.4-21.2)/100,000 and among women 69.6 (95% CI: 66-73.4)/100,000. A female preponderance of 3.4 existed among these patients. In the year 2005, 143 new cases were diagnosed, resulting in an incidence rate of 3.64/100,000. The mean age of onset was 25.36 +/- 8.6 years (range 5-63 year), and mean duration of disease was 7.1 (+/-5.2) years for men and 6.7 (+/-5) years for women. Sensory and visual disturbances were the most common initial presentations with a prevalence of 51.7% and 47.5%, respectively. Cases identified include: early-onset MS (less than 15 years old at onset) with 87 cases (5%), late-onset MS (over 50 years old at onset) with 20 cases (1.1%), familial MS with 209 cases (12.2%), and conjugal MS with 6 cases (0.5%).

CONCLUSION

Isfahan is a medium- to high-risk area for MS, with prevalence higher than what has previously been reported, possibly because of an increase in the incidence rate. Clinical and demographic characteristics were similar to other reports; however, some differences existed.

摘要

背景

本调查旨在研究伊朗伊斯法罕多发性硬化症(MS)的患病率和发病率,描述MS患者总体及特定亚组(早发型、晚发型、家族性和配偶性病例)的临床特征,并将我们的结果与其他报告进行比较。

方法

于2003年4月5日至2006年7月31日进行了一项横断面研究。所有根据麦克唐纳标准确诊为MS、在世、居住在伊斯法罕(伊朗的一个大省)且为伊斯法罕MS协会(IMSS)成员的患者均纳入本研究。记录了人口统计学和病例相关信息。从IMSS数据库中识别出1718例确诊的MS患者(388名男性和1330名女性)。

结果

MS的总体期间患病率为43.8/10万。男性患病率为19.2(95%可信区间:17.4 - 21.2)/10万,女性为69.6(95%可信区间:66 - 73.4)/10万。这些患者中女性优势比为3.4。2005年,诊断出143例新病例,发病率为3.64/10万。发病的平均年龄为25.36±8.6岁(范围5 - 63岁),男性疾病平均病程为7.1(±5.2)年,女性为6.7(±5)年。感觉和视觉障碍是最常见的初始表现,患病率分别为51.7%和47.5%。识别出的病例包括:早发型MS(发病年龄小于15岁)87例(5%),晚发型MS(发病年龄超过50岁)20例(1.1%),家族性MS 209例(12.2%),配偶性MS 6例(0.5%)。

结论

伊斯法罕是MS的中高风险地区,患病率高于先前报告的水平,可能是由于发病率增加。临床和人口统计学特征与其他报告相似;然而,也存在一些差异。

相似文献

1
Multiple sclerosis in Isfahan, Iran.伊朗伊斯法罕的多发性硬化症
Int Rev Neurobiol. 2007;79:357-75. doi: 10.1016/S0074-7742(07)79016-5.
2
Prevalence of multiple sclerosis in Isfahan, Iran.伊朗伊斯法罕多发性硬化症的患病率。
Neuroepidemiology. 2006;27(1):39-44. doi: 10.1159/000094235. Epub 2006 Jun 27.
3
Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran.伊朗伊斯法罕多发性硬化症发病率和患病率急剧上升。
Mult Scler. 2011 Aug;17(8):1022-7. doi: 10.1177/1352458511401460. Epub 2011 Apr 1.
4
Increasing female preponderance of multiple sclerosis in Isfahan, Iran: a population-based study.伊朗伊斯法罕多发性硬化症女性患者增多:基于人群的研究。
Mult Scler. 2010 Mar;16(3):359-61. doi: 10.1177/1352458509358092. Epub 2010 Jan 19.
5
Frequency of myasthenia gravis in multiple sclerosis: Report of five cases from Isfahan, Iran.多发性硬化症中的重症肌无力频率:来自伊朗伊斯法罕的五例报告。
Neurol India. 2009 Sep-Oct;57(5):638-40. doi: 10.4103/0028-3886.57817.
6
Conjugal multiple sclerosis in Isfahan, Iran: a population-based study.伊朗伊斯法罕的夫妻性多发性硬化症:一项基于人群的研究。
Mult Scler. 2007 Jun;13(5):673-5. doi: 10.1177/1352458506072092. Epub 2007 Feb 9.
7
Prevalence and incidence of multiple sclerosis in western Greece: a 23-year survey.希腊西部多发性硬化症的患病率和发病率:一项为期23年的调查。
Neuroepidemiology. 2008;30(3):167-73. doi: 10.1159/000122334. Epub 2008 Apr 2.
8
Increasing incidence of multiple sclerosis among women in Lorraine, Eastern France.法国东部洛林地区女性多发性硬化症发病率上升。
Mult Scler. 2007 Sep;13(8):962-7. doi: 10.1177/1352458507077938. Epub 2007 Jul 10.
9
Possible increasing risk of multiple sclerosis in Catania, Sicily.西西里岛卡塔尼亚地区多发性硬化症风险可能增加。
Neurology. 2005 Oct 25;65(8):1259-63. doi: 10.1212/01.wnl.0000180628.38786.85.
10
A 20-year incidence trend (1989-2008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: a population-based study.伊朗德黑兰多发性硬化症的 20 年发病趋势(1989-2008 年)和时点患病率(2009 年 3 月 20 日):一项基于人群的研究。
Neuroepidemiology. 2011;36(3):141-7. doi: 10.1159/000324708. Epub 2011 Apr 20.

引用本文的文献

1
Fuchs' uveitis syndrome: a 20-year experience in 466 patients.富克斯葡萄膜炎综合征:466例患者的20年经验。
Sci Rep. 2024 Apr 14;14(1):8621. doi: 10.1038/s41598-024-59393-w.
2
Demographic and Clinical Characteristics of Familial and Sporadic Multiple Sclerosis Patients.家族性和散发性多发性硬化症患者的人口统计学和临床特征
Int J Prev Med. 2023 Jun 22;14:86. doi: 10.4103/ijpvm.ijpvm_187_22. eCollection 2023.
3
Economic Burden of Multiple Sclerosis Drugs in Iran during 2011-2019.2011 - 2019年伊朗多发性硬化症药物的经济负担
Iran J Public Health. 2023 Feb;52(2):407-419. doi: 10.18502/ijph.v52i2.11894.
4
Clinical Profile and the Extent of Disability in Multiple Sclerosis Patients in Madinah, Saudi Arabia.沙特阿拉伯麦地那多发性硬化症患者的临床概况与残疾程度
Cureus. 2022 Jun 11;14(6):e25851. doi: 10.7759/cureus.25851. eCollection 2022 Jun.
5
COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021.2021 年 5 月伊朗多发性硬化症患者 COVID-19 感染和住院率:我们所了解的情况。
Mult Scler Relat Disord. 2022 Jan;57:103335. doi: 10.1016/j.msard.2021.103335. Epub 2021 Oct 16.
6
Apparent changes in the epidemiology and severity of multiple sclerosis.多发性硬化症的流行病学和严重程度的明显变化。
Nat Rev Neurol. 2021 Nov;17(11):676-688. doi: 10.1038/s41582-021-00556-y. Epub 2021 Sep 28.
7
The global prevalence of familial multiple sclerosis: an updated systematic review and meta-analysis.家族性多发性硬化症的全球患病率:一项更新的系统评价和荟萃分析。
BMC Neurol. 2021 Jun 28;21(1):246. doi: 10.1186/s12883-021-02267-9.
8
Multiple sclerosis in Iran: An epidemiological update with focus on air pollution debate.伊朗的多发性硬化症:聚焦空气污染争议的流行病学最新情况
J Clin Transl Res. 2021 Feb 17;7(1):49-60. eCollection 2021 Feb 25.
9
Age and sex-adjusted incidence and yearly prevalence of multiple sclerosis (MS) in Mazandaran province, Iran: An 11-years study.伊朗马赞达兰省年龄和性别调整后多发性硬化症 (MS) 的发病率和年患病率:一项 11 年的研究。
PLoS One. 2020 Jul 2;15(7):e0235562. doi: 10.1371/journal.pone.0235562. eCollection 2020.
10
Economic costs incurred by the patients with multiple sclerosis at different levels of the disease: a cross-sectional study in Northwest Iran.伊朗西北部多发性硬化症患者在疾病不同阶段产生的经济成本:一项横断面研究
BMC Neurol. 2020 May 23;20(1):205. doi: 10.1186/s12883-020-01790-5.